Back to Markets
ZNZentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

ZNTLNASDAQ NMS - GLOBAL MARKET
Health CareBiotechnology

$4.00

-0.050000 (-1.23%)

As of 05/29/26 EDT · USD

Compare
Low: $1.13Current: $4.00High: $6.95

Key Statistics

Open

$4.07

Day High

$4.10

Day Low

$3.94

Prev. Close

$4.05

VolumeShares traded today.

518.61K

Avg. VolumeAverage daily volume.

Market CapTotal value of all shares = price × shares outstanding.

$284.75M

P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.

-2.30

Forward P/EP/E based on forecast next-year earnings.

P/B RatioPrice-to-Book: share price ÷ book value per share.

52W HighHighest price over the past 52 weeks.

$6.95

52W LowLowest price over the past 52 weeks.

$1.13

50D MAAverage closing price over the last 50 trading days.

$3.78

200D MAAverage closing price over the last 200 trading days.

$2.36

Dividend YieldAnnual dividend ÷ share price, as a %.

BetaVolatility vs the market. >1 = more volatile than the S&P 500.

Performance

1W

-3.4%

1M

+1.0%

6M

+177.8%

YTD

+192.0%

1Y

+230.6%

About

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.

www.zentalis.com/

Company Facts

SectorHealth Care
IndustryBiotechnology
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD

Sentiment

Latest News

Social Noise

Price Alerts

Loading…

Trade ZNTL

Brokers available in your region (US)

Affiliate links — we may earn a commission. CFDs are risky.